C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease

E-ISSN： 1996-3181|17|1|14-21

ISSN： 1871-5273

Source： CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol.17, Iss.1, 2018-04, pp. : 14-21

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacological Prolyl Hydroxylase Domain Inhibition as a Therapeutic Target for Parkinson’s Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 13, Iss. 1, 2014-02 ,pp. : 120-125

Bentham Science Publishers

Access to resources Recommend Favorite

BCR-ABL as a target for novel therapeutic interventions

By Kindler T Meyer RG Fischer T

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 1, 2002-02 ,pp. : 85-101

Informa Healthcare

Access to resources Recommend Favorite

The parkin protein as a therapeutic target in Parkinson's disease

By Winklhofer Konstanze F

Expert Opinion on Therapeutic Targets, Vol. 11, Iss. 12, 2007-12 ,pp. : 1543-1552

Informa Healthcare

Access to resources Recommend Favorite

Neurotrophic factors as a therapeutic target for Parkinson's disease

By Evans Jonathan R Barker Roger A

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 4, 2008-04 ,pp. : 437-447

Informa Healthcare

Access to resources Recommend Favorite

The endothelin system:a novel therapeutic target in cardiovascular disease

By Strachan F.E. Webb D.J.

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 95-112

Informa Healthcare

Access to resources Recommend Favorite